NASDAQ · CAI
Healthcare · Biotechnology
$30.63
Down-$0.92 (-2.92%)
Updated Oct 1, 2026, 10:14 AM
SID Score
6.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CAI
1M range · 20 trading sessions · Daily adjusted prices
Prices through Sep 30, 2026
CAI closed at $30.63 after 20 trading sessions, up 23.51% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 30, 2026 | $31.40 | $32.04 | $30.60 | $30.63 | 2.93M |
| Sep 29, 2026 | $31.64 | $32.325 | $30.82 | $31.55 | 3.71M |
| Sep 28, 2026 | $31.73 | $32.09 | $30.88 | $31.75 | 3.94M |
| Sep 25, 2026 | $32.65 | $32.77 | $31.585 | $31.98 | 2.92M |
| Sep 24, 2026 | $31.34 | $32.405 | $30.91 | $32.27 | 5.98M |
| Sep 23, 2026 | $31.12 | $32.89 | $31.10 | $31.65 | 4.36M |
| Sep 22, 2026 | $31.55 | $32.36 | $31.33 | $31.47 | 5.96M |
| Sep 21, 2026 | $30.23 | $30.71 | $29.97 | $30.65 | 6.15M |
| Sep 18, 2026 | $30.29 | $30.99 | $29.69 | $29.98 | 14.72M |
| Sep 17, 2026 | $28.595 | $31.36 | $28.53 | $30.92 | 7.66M |
| Sep 16, 2026 | $28.16 | $29.085 | $27.91 | $28.21 | 4.3M |
| Sep 15, 2026 | $25.80 | $28.675 | $25.80 | $28.50 | 8.84M |
| Sep 14, 2026 | $24.24 | $26.18 | $24.05 | $26.05 | 3.64M |
| Sep 11, 2026 | $24.16 | $24.67 | $24.09 | $24.34 | 1.82M |
| Sep 10, 2026 | $23.20 | $24.68 | $23.20 | $24.04 | 2.63M |
| Sep 9, 2026 | $24.00 | $24.96 | $23.95 | $24.03 | 3.15M |
| Sep 8, 2026 | $25.03 | $25.68 | $24.74 | $24.82 | 4.58M |
| Sep 4, 2026 | $24.88 | $25.14 | $24.4718 | $25.07 | 4.71M |
| Sep 3, 2026 | $24.94 | $25.34 | $23.62 | $25.32 | 6.43M |
| Sep 2, 2026 | $25.13 | $25.615 | $24.505 | $24.80 | 5.49M |
The latest Smart Investors Daily articles mentioning CAI.
Company
Market Activity
Research & News
CAI research
Company profile and research snapshot.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jul 2, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 22, 2026
In general, many current shareholders have lived through a deep correction that started after Caris Life Sciences peaked at 42.50 on Aug. 22 last year. Thus, Caris Life Sciences is still extended. Caris Life Sciences uses artificial intelligence and other technology to profile molecules of interest to the life sciences industry.
SeekingAlpha · Sep 22, 2026
Caris Life Sciences' Q2 featured accelerating clinical volumes, 68% gross margin, and strong early traction for Caris Detect. Read why CAI stock is a Hold.
Yahoo · Sep 18, 2026
Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.
Yahoo · Sep 18, 2026
Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAI.
